Redigerer Sinopharms COVID-19-vaksine (BBIBP-CorV) (avsnitt)

==Utvikling, klinisk testing==
Fra juli 2020 pågikk fase III-studier i De forente arabiske emirater,<ref name=uae/> Bahrain,<ref>{{cite web |title=Bahrain starts Phase III trial of Sinopharm's Covid-19 vaccine |url=https://www.clinicaltrialsarena.com/news/bahrain-vaccine-trial-sinopharm/ |website=Clinical Trials Arena |date=24. august 2020}}</ref> [[Jordan]],<ref name="multiple">{{cite web| vauthors = Liu R |date=5. september 2020|title=China's CNBG, Sinovac find more countries to test coronavirus vaccines|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-china/chinas-cnbg-sinovac-find-more-countries-to-test-coronavirus-vaccines-idUSKBN25W0BA|access-date=6. september 2020|website=Reuters|language=}}</ref><ref>{{Cite web|date=2020-08-30|title=Jordan starts phase 3 trial of China's COVID-19 vaccine|url=http://www.jordantimes.com/news/local/jordan-starts-phase-3-trial-chinas-covid-19-vaccine|access-date=2021-01-27|website=Jordan Times|language=}}</ref> [[Egypt]]<ref>{{Cite web|date=2020-09-12|title=Egypt to start receiving volunteers for COVID-19 vaccine trials|url=https://egyptindependent.com/egypt-to-start-receiving-volunteers-for-covid-19-vaccine-trials/|access-date=2021-01-27|website=Egypt Independent|language=}}</ref> Pakistan<ref name="geo.tv">{{Cite web|title=Coronavirus vaccine should be available in Pakistan 'within 6-8 weeks'|url=https://www.geo.tv/latest/317958-covid-19-vaccine-will-be-available-in-pakistan-within-six-to-eight-weeks-claims-uhs-vc-dr-javed-akram|access-date=2020-11-14|website=www.geo.tv|language=}}</ref> og Argentina<ref>{{Cite web|title=Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT04560881|access-date=2021-01-27|website=clinicaltrials.gov|language=}}</ref>

'''Autorisasjon for nødbruk:''' Tillatelse for nødbruk ble gitt av Kina i juli 2020<ref>{{Tidningsref|datum=2020-08-29|titel=Sinovac's coronavirus vaccine candidate approved for emergency use in China - source|språk=|tidning=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-china-vaccines-idUSKBN25O0Z3|hämtdatum=2021-01-27}}</ref> oktober 2020,<ref>{{cite web | vauthors = Vivek V |title=China's Sinopharm offers experimental COVID-19 vaccines to students: WSJ |url=https://www.reuters.com/article/us-health-coronavirus-china-vaccine/chinas-sinopharm-offers-experimental-covid-19-vaccines-to-students-wsj-idUSKBN27003J |publisher=Reuters |access-date=27. januar 2021|language=|date=15. oktober 2020}}</ref><ref>{{Cite web| vauthors = Chen F |date=2020-10-20|title=Chinese province set to roll out jabs against Covid|url=https://asiatimes.com/2020/10/chinese-province-set-to-roll-out-jabs-against-covid/|access-date=2021-01-27|website=Asia Times|language=}}</ref>, De forente arabiske emirater<ref name=uae>[https://www.nature.com/articles/d41586-020-03563-z ''Arab nations first to approve Chinese COVID vaccine — despite lack of public data'' i Nature den 14. desember 2020]</ref> og Bahrain i november<ref name="Bahrain">[https://www.reuters.com/article/health-coronavirus-bahrain/update-1-bahrain-approves-registration-for-sinopharm-covid-19-vaccine-idUSL1N2IT04F ''Bahrain approves registration for Sinopharm COVID-19 vaccine'' på www.reuters.com den 13. desember 2020]</ref>

Wuhan Institute of Biological Products publiserte den 13. august interimsresultater for sine Fase I- og Fase II-studier med 96 respektive 224 voksne. <ref name=":1">{{cite journal | vauthors = Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X | display-authors = 6 | title = Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials | journal = JAMA | volume = 324 | issue = 10 | pages = 951–960 | date = september 2020 | pmid = 32789505 | doi = 10.1001/jama.2020.15543 | pmc = 7426884 | doi-access = free }}</ref> 

Beijing Institute of Biological Products publiserte den 15. oktober 2020 resultat fra sin Fase I-studie med 192 voksne og sin Fase II-studie med 448 voksne for BBIBP-CorV-vaksinen.<ref name=":0">{{cite journal | authors = Xia S, [et al.]| title = Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial | journal = The Lancet. Infectious Diseases | date = oktober 2020 | volume = 21 | pages = 39–51 | pmid = 33069281 | doi = 10.1016/s1473-3099(20)30831-8 | pmc = 7561304 }}</ref>

Sinopharm meldte 30. desember 2020 at BBIBP-CorV-vaksinen hadde en beskyttelsesgrad på 79,34 %, lavere enn tallet 86 % som myndighetene i De forente arabiske emirater hadde oppgitt den 9. desember på basis av en midlertidig analyse.<ref>{{Cite web|author=Nectar Gan|title=China's Sinopharm says its coronavirus vaccine is 79% effective|url=https://www.cnn.com/2020/12/30/asia/china-sinopharm-vaccine-efficacy-intl-hnk/index.html|access-date=2021-01-26|website=CNN}}</ref> 

Vaksinen hadde per desember 2020 i fase III-forsøk i blant annet [[Argentina]], [[Bahrain]], [[Egypt]], [[Marokko]], [[Pakistan]], [[Peru]] og [[De forente arabiske emirater]] med flere enn 60&nbsp;000 deltakere.<ref name=":5">{{Tidningsref|författare= Reuters Staff |datum=2020-11-19|titel=China Sinopharm's coronavirus vaccine taken by about a million people in emergency use|språk=|tidning=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm-idUSKBN27Z0PY|hämtdatum=2021-01-26}}</ref> Kinesiske myndigheter hadde tidligere godkjent vaksinen for akuttbruk; per november 2020 hadde en million kinesere fått vaksinen.<ref name=":5" /> Per desember 2020 var også ca 100&nbsp;000 personer i De forente arabiske emirater blitt vaksinerte.<ref name=":9">{{Cite web|author=Mostafa Salem and Yong Xiong|title=China's Sinopharm vaccine has 86% efficacy against Covid-19, says UAE|url=https://www.cnn.com/2020/12/09/asia/uae-china-vaccine-intl-hnk/index.html|access-date=2021-01-27|website=CNN}}</ref>